Manufacturing Onshoring

Overview

The geopolitical trend driving pharmaceutical and biologic manufacturers to establish or relocate production within the US or regional markets, creating unprecedented capital investment particularly in North Carolina and Indiana and intensifying competition for biomanufacturing talent. The combination of onshoring pressure and GLP-1 demand is driving unprecedented US biomanufacturing investment — particularly in North Carolina (six or seven major facility announcements) and Indiana — at a scale John Matulsky describes as unlike anything in his 25-year career. Biomanufacturing facility construction is competing with data center construction for the same pool of tradespeople — electricians and pipefitters — driving up capital costs during the current US onshoring investment wave. (Segment 8 (35:00-40:00))